EVAX
NASDAQEvaxion A/S
Price$3.02-1.00 (-25.00%)
2026-04-142026-07-17
News · 26 weeks59+50%
2026-01-182026-07-12
Mix2090d
- SEC Filings10(50%)
- Other7(35%)
- Insider1(5%)
- Earnings1(5%)
- Offering1(5%)
Latest news
25 items- SECSEC Form 6-K filed by Evaxion A/S6-K - Evaxion A/S (0001828253) (Filer)
- PREvaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune responseData will also offer insight into the vaccine’s effect also as stand-alone treatment of patients with advanced melanomaUnprecedented two-year data from the trial presented last year showed high response rates and an impressive durability of responses COPENHAGEN, Denmark, July 17, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present three-year clinical efficacy data from its phase 2 trial with personalized cancer vaccine
- SECSEC Form 6-K filed by Evaxion A/S6-K - Evaxion A/S (0001828253) (Filer)
- PREvaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1The new data demonstrates the potential to improve control of acute infection, latency, and viral reactivation, further supporting the concept behind EVX-V1EVX-V1 is a next-generation, multi-component vaccine program combining novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigensData presented today in poster presentation at the International Herpesvirus Workshop 2026 taking place in Montreal, Canada COPENHAGEN, Denmark, July 12, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, presents new data further supporting the multi-component concept of its cytom
- SECSEC Form 6-K filed by Evaxion A/S6-K - Evaxion A/S (0001828253) (Filer)
- PREvaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus WorkshopNew preclinical data will guide antigen selection for a broadly protective cytomegalovirus vaccine candidatePoster presentation on July 12, 2026, at the International Herpesvirus Workshop 2026 taking place in Montreal, Canada COPENHAGEN, Denmark, July 1, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present new preclinical data for vaccine candidate EVX-V1 in a poster session at the International Herpesvirus Workshop (IHW) 2026 taking place in Montreal, Canada, July 11-15, 2026. EVX-V1 is a next-generation, multi-component cytomegalovirus (CMV) vaccine candidate combining novel AI-d
- SECSEC Form 6-K filed by Evaxion A/S6-K - Evaxion A/S (0001828253) (Filer)
- PREvaxion receives Prix Galien UK Award for Best digital health solutionCOPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has been awarded the 2026 Prix Galien UK Award for Best digital health solution for AI-Immunology™. The award is another strong external validation and recognition of the AI-Immunology™ platform, which harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases. The award was received by Evaxion CEO Helen-Tayton Martin at the Prix Galien UK Awards ceremony at the Natural History Museum in London. Evaxion and AI-Immunology
- SECSEC Form 6-K filed by Evaxion A/S6-K - Evaxion A/S (0001828253) (Filer)
- PREvaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemiaEVX-04 is successfully expressed and secreted in human cells enabling immune recognition and activationThe vaccine antigens drive specific immune responses across different human immune profiles and induce targeted cell-killing Poster presentation at the European Hematology Association (EHA) 2026 Congress, taking place in Stockholm, Sweden COPENHAGEN, Denmark, June 11, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML). Developed with AI-Immunology™, EVX-04 targets multiple non-conv
- SECSEC Form 6-K filed by Evaxion A/S6-K - Evaxion A/S (0001828253) (Filer)
- PREvaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 CongressData will reflect the functional characterization of EVX-04Poster presentation on June 13, 2026 COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will announce the functional characterization of EVX-04, an off-the-shelf therapeutic acute myeloid leukemia (AML) vaccine, in a poster presentation at the European Hematology Association (EHA) 2026 Congress taking place in Stockholm, Sweden, June 11-14, 2026. The new preclinical data will represent another step towards clinical testing of EVX-04. Evaxion plans to submit a clinical trial application in the second half o
- SECSEC Form 6-K filed by Evaxion A/S6-K - Evaxion A/S (0001828253) (Filer)
- PREvaxion announces business update and first quarter 2026 financial resultsCOPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces first quarter 2026 financial results. Business highlights (since last quarterly update)Evaxion has had a good start to the year executing on our plans and achieving our first milestone for 2026 as expected. Highlights include: New data demonstrating an 86% vaccine target recognition by AI-Immunology™ in personalized cancer vaccine EVX-01 is a further scientific validation of the platform's precision in driving immune response. This marked our first milestone for the yearAnothe
- SECSEC Form 6-K filed by Evaxion A/S6-K - Evaxion A/S (0001828253) (Filer)
- PREvaxion to announce business update and first quarter 2026 financial results on May 7, 2026COPENHAGEN, Denmark, May 4, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its first quarter 2026 financial results on Thursday May 7, 2026, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be acces
- SECSEC Form 6-K filed by Evaxion A/S6-K - Evaxion A/S (0001828253) (Filer)
- PREvaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating OfficerManagement remit expansion reflecting organization alignment to maximize external engagement and strategy execution COPENHAGEN, Denmark, April 27, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, that Birgitte Rønø, its Chief Scientific Officer (CSO), will take on the dual responsibilities of CSO and Chief Operating Officer (COO). The promotion follows an internal management review of the optimal way of working to continue to deliver Evaxion's strategy through broader external visibility of the power of the AI-Immunology™ platform with partners and investors. It also reflects the recognitio
- INSIDERNew insider Bitsch-Norhave Jens claimed ownership of 2,376 units of Ordinary Shares (SEC Form 3)3 - Evaxion A/S (0001828253) (Issuer)
- SECSEC Form 6-K filed by Evaxion A/S6-K - Evaxion A/S (0001828253) (Filer)
- SECSEC Form 6-K filed by Evaxion A/S6-K - Evaxion A/S (0001828253) (Filer)
- SECSEC Form 6-K filed by Evaxion A/S6-K - Evaxion A/S (0001828253) (Filer)
- PREvaxion's AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trialNew phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune responseThe results reinforce that Evaxion's pioneering AI platform, AI-Immunology™ accurately identifies and selects the most relevant vaccine targetsData will be presented at the American Association for Cancer Research (AACR) Annual Meeting COPENHAGEN, Denmark, April 17, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new data demonstrating that AI-Immunology™ identifies and selects the most therapeutically relevant vaccine targets. The
- PRNew data demonstrates the unique scalability of Evaxion's AI-Immunology™ platform in glioblastomaData analysis conducted in collaboration with a leading academic medical center shows that AI‑Immunology™ enables vaccine design also for the deadly brain cancer, glioblastomaUniquely, the platform can identify a novel source of targets to include in glioblastoma cancer vaccines, potentially enhancing their efficacyData will be presented at the American Association for Cancer Research (AACR) Annual Meeting COPENHAGEN, Denmark, April 17, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new data demonstrating the platform's ability to also potentially develop vaccines for glioblastom
- SECSEC Form 6-K filed by Evaxion A/S6-K - Evaxion A/S (0001828253) (Filer)
EVAX FAQ
7 questionsWhat does Evaxion A/S do?
Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer...Where does EVAX stock trade?
Evaxion A/S (EVAX) is listed on NASDAQ.What sector and industry is EVAX in?
Evaxion A/S operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Evaxion A/S go public?
Evaxion A/S (EVAX) completed its IPO in 2021.What are analysts saying about EVAX?
Evaxion A/S has had 3 recent analyst actions on file. The most recent action was from Maxim Group: Buy with a $1000.00 price target on 2026-02-19. Recent price targets range from $800.00 to $1400.00.What companies are similar to EVAX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare EVAX side-by-side with any of them on Quantisnow.How can I track EVAX on Quantisnow?
Quantisnow aggregates Evaxion A/S's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EVAX to receive live email and push alerts on every new disclosure.